Today, Merck & Co Inc (MRK.N) said it has applied for U.S. emergency use authorization for its drug to treat mild-to-moderate patients of COVID-19. You heard that right, in a time that we clearly are not in an emergency - more drugs are being fast-tracked whilst still being in their trial stage. Remember, if these drugs did not have the ONLY FOR EMERGENCY USE label on them it would be ILLEGAL for most governments to give them to you.
This is going to become the first oral antiviral medication for the clotshot. It will come as no surprise that the US FDA (Food and Drug Administration) will give it the authorization that Merck is longing for.
The drug, molnupiravir, is said to help cut death rates by 50% of mild to moderately ill patients that have at least one underlying health conditions that would increase their chances of getting ill with convid. It is interesting that they have chosen to mention underlying health conditions, as for the past 18-months the powers that be have mainly refused to acknowledge these factors.
We always say follow the money and this little scam is no different. The drugmaker has already got a U.S. government contract to supply 1.7 million courses at a staggering price of $700 per course. Merck expects to produce 10 million courses of the treatment by the end of 2021. THIS YEAR!